Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-25-085149
Filing Date
2025-09-05
Accepted
2025-09-05 17:20:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 9489
  Complete submission text file 0001213900-25-085149.txt   11420
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-79364 | Film No.: 251297530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 120 NEWPORT CENTER DRIVE STE. 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE. 250 NEWPORT BEACH CA 92660 888-445-4886
PMGC CAPITAL LLC (Filed by) CIK: 0002068010 (see all company filings)

EIN.: 331978501 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D/A